NCCN Guidelines® Insights - Chronic Myelogenous Leukemia, Version 1.2014
The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (qRT-PCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with qRT-PCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with qRT-PCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for CML
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for CML
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician